WHITEHAWK THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.52M, a 50.76% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.19M, a 30.54% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.72M, a 6.30% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.09M, a 8.74% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.87M, a 8.91% decline from fiscal 2024.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.84M, a 9.33% decline from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.95M, a 23.97% increase from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $9.64M, a 357.88% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.52M 10-Q · filed 2026-08-06 | $3.71M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.19M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $9.87M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $2.72M 10-Q · filed 2025-11-06 | $5.80M derived: sum of 2 quarters · filed 2026-08-06 | $7.49M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $3.09M 10-Q · filed 2026-08-06 | $4.77M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.68M 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $10.84M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $2.56M 10-Q · filed 2025-11-06 | $5.40M derived: sum of 2 quarters · filed 2025-11-06 | $8.98M derived: sum of 3 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $2.84M 10-Q · filed 2025-11-06 | $6.43M derived: sum of 2 quarters · filed 2025-11-06 | ||||
| 2024-03-31 | $3.59M 10-Q · filed 2025-11-06 | |||||
| 2023-12-31 | $11.95M 10-K · filed 2025-03-28 | |||||
| 2023-09-30 | $3.05M 10-Q · filed 2024-11-06 | $6.10M derived: sum of 2 quarters · filed 2024-11-06 | $8.84M derived: sum of 3 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $3.05M 10-Q · filed 2024-11-06 | $5.79M derived: sum of 2 quarters · filed 2024-11-06 | ||||
| 2023-03-31 | $2.74M 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | $9.64M 10-K · filed 2024-03-13 | |||||
| 2022-09-30 | $2.76M 10-Q · filed 2023-11-08 | $4.99M derived: sum of 2 quarters · filed 2023-11-08 | $6.77M derived: sum of 3 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $2.23M 10-Q · filed 2023-11-08 | $4.02M derived: sum of 2 quarters · filed 2023-11-08 | ||||
| 2022-03-31 | $1.78M 10-Q · filed 2023-11-08 | |||||
| 2021-12-31 | $2.11M 10-K · filed 2023-03-29 | |||||
| 2021-09-30 | $648.00K 10-Q · filed 2022-11-09 | $687.00K derived: sum of 2 quarters · filed 2022-11-09 | $723.00K derived: sum of 3 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $39.00K 10-Q · filed 2022-11-09 | $557.22K 10-Q · filed 2021-08-11 | $75.00K derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $36.00K 10-Q · filed 2022-11-09 | $345.76K 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $139.00K 10-K · filed 2022-03-17 | $1.28M 10-K · filed 2021-03-11 | ||||
| 2020-09-30 | $34.00K 10-Q · filed 2021-11-10 | $332.14K 10-Q · filed 2020-11-10 | $71.00K derived: sum of 2 quarters · filed 2021-11-10 | $100.00K derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $37.00K 10-Q · filed 2021-11-10 | $308.34K 10-Q · filed 2020-08-12 | $66.00K derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $29.00K 10-Q · filed 2021-11-10 | $327.47K 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $1.09M 10-K · filed 2021-03-11 | |||||
| 2019-09-30 | $645.90K 10-Q · filed 2020-11-10 | $1.25M derived: sum of 2 quarters · filed 2020-11-10 | $1.87M derived: sum of 3 quarters · filed 2020-11-10 | $2.54M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $604.66K 10-Q · filed 2020-11-10 | $1.23M derived: sum of 2 quarters · filed 2020-11-10 | $1.89M derived: sum of 3 quarters · filed 2020-11-10 | $2.70M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $621.68K 10-Q · filed 2020-11-10 | $1.29M derived: sum of 2 quarters · filed 2020-11-10 | $2.10M derived: sum of 3 quarters · filed 2020-11-10 | $2.97M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2018-12-31 | $667.97K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.47M derived: sum of 2 quarters · filed 2020-03-16 | $2.35M derived: sum of 3 quarters · filed 2020-03-16 | $3.43M 10-K · filed 2020-03-16 | ||
| 2018-09-30 | $806.41K 10-Q · filed 2019-11-07 | $1.68M derived: sum of 2 quarters · filed 2019-11-07 | $2.76M 10-Q · filed 2018-11-07 | $3.02M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $877.76K 10-Q · filed 2019-11-07 | $1.96M 10-Q · filed 2018-08-14 | $2.21M derived: sum of 3 quarters · filed 2019-11-07 | $2.34M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $1.08M 10-Q · filed 2019-11-07 | $1.33M derived: sum of 2 quarters · filed 2019-11-07 | $1.46M derived: sum of 3 quarters · filed 2019-11-07 | $1.57M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2017-12-31 | $255.14K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $382.50K derived: sum of 2 quarters · filed 2019-03-07 | $494.02K derived: sum of 3 quarters · filed 2019-03-07 | $649.41K 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $127.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $238.88K derived: sum of 2 quarters · filed 2017-11-13 | $394.27K 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $111.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $266.91K 10-Q · filed 2017-08-10 | ||||
| 2017-03-31 | $155.38K 10-Q · filed 2017-05-15 | |||||
| 2016-12-31 | $488.33K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |